Ovid Therapeutics, Inc.

As of September 3, 2025, Ovid Therapeutics has shifted to a bullish trend with strong short-term performance, showing a 30.79% return over the past month, but it has underperformed the S&P 500 over the longer term with returns of -41.35% and -81.76% over 3 and 5 years, respectively.

As of August 13, 2025, Ovid Therapeutics, Inc. is considered risky and overvalued due to negative financial indicators, including a price-to-book value of 0.38, an EV to EBITDA ratio of 0.34, a return on equity of -33.92%, and a significant underperformance of -81.76% over five years compared to the S&P 500's 96.61% return.

As of May 5, 2023, Ovid Therapeutics, Inc. is considered overvalued with a significant downgrade in investment appeal, reflected by a negative ROE of -33.92%, a Price to Book Value of 0.38, and a year-to-date stock return of -68.94%, underperforming the S&P 500.

As of June 2, 2025, the market trend is mildly bearish, with mixed signals from indicators like the MACD, RSI, and moving averages, suggesting caution in the near term.

As of March 2022, Ovid Therapeutics, Inc.'s management team includes Dr. Jeremy Levin as Chairman and CEO, Mr. Bart Friedman as Lead Independent Director, and Drs. Karen Bernstein, Barbara Duncan, and Douglas Williams as Independent Directors.

Ovid Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for rare neurological disorders. It has a market cap of $21.50 million and reported net sales of $0 million with a net loss of $10 million as of March 2025.

As of Jun 18, Ovid Therapeutics, Inc. has a market capitalization of 21.50 million, with recent net sales of 0.55 million and a net profit of -24.97 million for the four quarters ending in March 2025. As of December 2024, the company reported shareholder's funds of 68.23 million and total assets of 92.17 million.